Administration of Cisplatin-Based Chemotherapy for Advanced Urothelial Carcinoma in the Community

Micro-Abstract Because the frequency of first-line cisplatin-based chemotherapy administration in patients with advanced urothelial carcinoma is unknown, a retrospective study was conducted. A first-line cisplatin-based regimen was administered to 35.9% of patients who presented with stage 4 urothel...

Full description

Saved in:
Bibliographic Details
Published in:Clinical genitourinary cancer 2012-03, Vol.10 (1), p.1-5
Main Authors: Sonpavde, Guru, Watson, Deidre, Tourtellott, Marcia, Cowey, C. Lance, Hellerstedt, Beth, Hutson, Thomas E, Zhan, Feng, Vogelzang, Nicholas J
Format: Article
Language:English
Subjects:
Adult
Advanced urothelial carcinoma
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carboplatin
Carboplatin - administration & dosage
Carcinoma, Transitional Cell - drug therapy
Carcinoma, Transitional Cell - secondary
Chemotherapy
Cisplatin
Cisplatin - administration & dosage
Female
First-line
Follow-Up Studies
Hematology, Oncology and Palliative Medicine
Humans
Male
Middle Aged
Retrospective Studies
Treatment Outcome
Urologic Neoplasms - drug therapy
Urologic Neoplasms - pathology
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Micro-Abstract Because the frequency of first-line cisplatin-based chemotherapy administration in patients with advanced urothelial carcinoma is unknown, a retrospective study was conducted. A first-line cisplatin-based regimen was administered to 35.9% of patients who presented with stage 4 urothelial carcinoma in a community-based cancer center network. Drug development focused on tolerable agents or combination regimens without a cisplatin backbone should be a priority.
ISSN:1558-7673
1938-0682
DOI:10.1016/j.clgc.2011.11.005